Unknown PHASE3 INTERVENTIONAL 2-arm NCT00376870

PIoglitazone for PrEvention of Restenosis in Diabetic Patients

Prevention of Coronary Artery in STENT Restenosis With the Combined Use of Pioglitazone and Sirolimus-Eluting Coronary Stent

Sponsor: University of Rome Tor Vergata

Conditions Coronary Atherosclerosis Coronary Restenosis Diabetes

Interventions Pioglitazone Placebo

Updated 6 times since 2017 Last updated: Jul 30, 2008 Started: Jul 31, 2008 Primary completion: Dec 31, 2010 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Coronary Atherosclerosis and Coronary Restenosis, this trial is ongoing. The trial is conducted by University of Rome Tor Vergata and has accumulated 6 data snapshots since 2008. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE3

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Rome Tor Vergata

Data source: University of Rome Tor Vergata

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rome, Italy